47 episodes
The MattCorc Podcast Life Sciences Rush Hour - Inve
-
- Business
A daily, 5-10 minute, podcast where we talk about risk and investing. Find out more at mattcorc.com or shoot me an email at matt@mattcorc.com. I would love to hear any feedback, including topic suggestions and insurance questions. If you would like to join me on an episode, send me an email.
-
Where does the market go from here? Will retail investors sell?
We talk about the recent market turmoil and how that will impact investor actions. Will investors stick to their guns or succumb and sell if the market continues to sell off. A few comments on Medtronic’s settlement and how insurance could have been implemented to reduce the financial burden for Medtronic.
-
What’s the deal with GE?
GE has seen its market cap decrease by over $200B since 2016 and it now trades at around $8. Is this the correct value or should it be higher or perhaps lower?
-
We changed our name and Amazon announced their new locations!
Why we changed our name to the MattCorc Podcast. Who is taking the most risk with the Amazon headquarters, Amazon or the local/state government? What is Waymo? The first autonomous ride hailing service is getting ready to launch in Arizona.
-
A $500 Million Biotech IPO. Amarin Data
Moderna plans the biggest biotech IPO ever and we learn more about Amarin’s clinical study. Was mineral oil the best choice of placebo? Lessons we can learn from Amarin about D&O insurance.
-
Herd Mentality. Why D&O benchmarking is a sales ploy. What to use to make a more informed decision.
I talk about how brokers use benchmarking to sell you more D&O insurance. Brokers take advantage of herd mentality so insurers buy more D&O than they need.
-
Why cost should only be one consideration
Cost and its importance are discussed. Minor differences in coverage can cause major headaches when you have a claim.